

Blood Cells, Molecules, and Diseases

Copyright © 2009 Elsevier Inc. All rights reserved.

Force Majeure: Therapeutic measures in response to restricted supply of imiglucerase (Cerezyme) for patients with Gaucher disease [☆]

Carla E.M. Hollak^a, Stephan vom Dahl^b, Johannes M.F.G. Aerts^c, Nadia Belmatoug^d, Bruno Bembi^e, Yossi Cohen^f, Tanya Collin-Histed^g, Patrick Deegan^h, Laura van Dussen^a, Pilar Giraldoⁱ, Eugen Mengelⁱ, Helen Michelakakis^k, Jeremy Manuel^g, Martin Hrebicek^l, Rosella Parini^m, Jörg Reinke^o, Maja di Rocco^p, Miguel Pociⁿ, Maria Clara Sa Miranda^q, Anna Tylki-Szymanska^r, Ari Zimran^s and Timothy M. Cox^h

^aDepartment of Endocrinology and Metabolism, Academic Medical Centre, F5-170, PO Box 22660, 1100 DD Amsterdam, The Netherlands

^bKlinik für Innere Medizin, St. Franziskus-Hospital, Köln, Germany

^cDepartment of Medical Biochemistry, Academic Medical Center, Amsterdam, The Netherlands

^dReference Center for Lysosomal Diseases, Hôpital Beaujon, Clichy, France

^eCentro di Coordinamento Regionale per le Malattie Rare, Ospedale Universitario, S. Maria della Misericordia, Udine, Italy

^fEGA and Israeli Gaucher Association, UK

^gEGA and Gauchers Association, UK

^hDepartment of Medicine, Addenbrooke's Hospital, University of Cambridge, UK

ⁱHospital Universitario Miguel Servet, Zaragoza. CIBERER, Spain

^jVilla metabolica, University Medical Center, Mainz, Germany

^kDepartment of Enzymology and Cellular Function, Institute of Child Health, Athens, Greece

^lInstitute of Inherited Metabolic Disorders, Charles University and General University Hospital, Prague, Czech Republic

^mRare Metabolic Diseases Unit "Fondazione Mariani", Pediatric Unit, San Gerardo Hospital, Monza, Italy

ⁿUniversity of Zaragoza. CIBERER. Spain

^oVilla metabolica, University Medical Center, Mainz, Germany

^pDepartment of Pediatrics, Gaslini Institute, Genoa, Italy

^qLysosome and Peroxisome Biology Unit, Instituto de Biologia Molecular Celular, Porto University, Porto, Portugal

^rClinics of Metabolic Diseases, Endocrinology and Diabetology The Children's Memorial Health Institute, Warsaw, Poland

^sShaare Zedek Medical Center, Jerusalem, Israel

Received 14 September 2009;

revised 22 September 2009.

(Communicated by A. Zimran, M.D., 22 September 2009).

Available online 4 October 2009.

Abstract

Gaucher disease is the first lysosomal disorder for which clinically effective enzyme replacement therapy has been introduced. Lifelong treatment with imiglucerase, the recombinant glucocerebrosidase manufactured by the Genzyme Corporation (MA, USA), is administered intravenously — usually at biweekly intervals. An acute shortage of imiglucerase (to 20% of prior global supply) has occurred as a result of viral contamination of the production facility; production was halted, and a full supply of imiglucerase is not anticipated until January 2010. An urgent meeting of physicians, researchers, and patients was convened through the agency of the European Working Group for Gaucher Disease; this was instigated by patients internationally represented by the European Gaucher Alliance. Here we present a position statement based on the findings of the group, with key recommendations about identification and monitoring of at-risk patients threatened by the abrupt withdrawal of treatment, the equitable distribution of residual imiglucerase — and access to alternative treatments including those that have completed phase III clinical trials but have not yet been licensed.

Keywords: Gaucher disease; Cerezyme; Imiglucerase; Vesivirus; Europe

Abbreviations: CEAP, Cerezyme Emergency Access Program; ECAP, European Cerezyme Access Program; EGA, European Gaucher Alliance; EMEA, European Medicines Agency; ERT, enzyme replacement therapy; EWGGD, European Working Group on Gaucher Disease; ESGLD, European Study Group on Lysosomal Diseases; FDA, Food and Drug Administration; GD, Gaucher disease; h-GCD, human cell-derived glucocerebrosidase (velaglucerase); ICGG, International Collaborative Gaucher Group; MPS II, mucopolysaccharidosis type II, Hunter disease; NP-C disease, Niemann-Pick disease type C; pr-GCD, plant-cell derived human glucocerebrosidase (taliglucerase); SRT, substrate reduction therapy